Autolus Therapeutics
Autolus Therapeutics

Autolus Therapeutics Information

Contact top employees from Autolus Therapeutics

Summary

Autolus Therapeutics is a public company that has been in the industry for 11 years. The company currently specializes in the Biotechnology, Biotechnology areas. The position of the Chairman & CEO is occupied by Christian Itin. Its headquarters is located at London, England, GB. The number of employees ranges from 250 to 500. The annual revenue of Autolus Therapeutics varies between 100K and 5.0M. Total funding of the company - $320.7M. To connect with Autolus Therapeutics employee register on SignalHire.

Organization Website

autolus.com

Social Links

linkedIn

Phone Number

44-20-3829-6230

Industries

Headquarters Location

Autolus Limited, London, W12 7RZ GB

Employees Size

500-1000 employees

SIC Code

2836

Founded

2014

Estimated Annual Revenue

$100K - 5.0M

Operating Status

Independent Company

Competitors

Founded
Type
Employees
Revenue
Funding
1979Public
Company
250 - 500 6.5M $296.4M
2009Public
Company
1.0K - 5.0K 45M $634.9M
2008Privately
Held
25 - 100 2.2M $160.5M
1994Public
Company
100 - 250 9.8M $251.2M

Employees Turnover 3 quarter 2025

Number of employees switched from or switched to
arrow
Total number all of employee turnover
Number of employees by department
arrow
Total number all of employee turnover
Length of Employment
arrow
Employee tenure at Autolus Therapeutics shows a diverse range of experience levels:
4% have been with the company for less than 1 year26% for 1–2 years21% for 3–4 years34% for 5–7 years9% for 8–10 years6% have over 11 years of service at Autolus Therapeutics
Ex-employees positions
In Company
In New Company
Contact top employees from Autolus Therapeutics
Todd Bittiger
Head of Procurement - Commercial and Medical Affairs
View
Jason Schwier
Vice President, Cell Therapy
View
Shasta Rizzi
Associate Director, IT Business Analyst
View
Timothy Porter
Medical Science Liaison
View
Teresa Chism
Case Manager - Car T Patient & Customer Support
View
Richard Gonzalez
Workplace Technology Specialist
View
Cintia Piccina
US General Manager and Chief Commercial Officer
View
Harolynn Adeniran
Senior Director, Center Onboarding and Alliance Management
View
Teresa
Director, Payer Access Cell Therapy
View
Mark
VP, Chief Information Officer
View
Christian Lang
Senior Director, Strategic Center Engagement
View
Brent Rice
SVP, Chief Commercial Officer, Managing Director Autolus US
View
Mark Prygoda
Senior Director, US Market Access Strategy & Operations
View
Capri Martinez
IT Operations Project Manager
View
Carrie Syfert
Patient Scheduler and Logistics Specialist
View
Dale Lippert Sr
Senior Director, CAR T Patient and Customer Support
View
Leslie Mann
Director, Payer Access Cell Therapy
View
Zaki Mahmood
Senior Director, Distribution, Pricing & Operations
View
George Amores
Cell Therapy Account Executive
View
Crystal Johans
Cell Therapy Account Executive
View
Ashley Wood
CAR T Case Manager
View
Erwin Espiritu
Clinical Site Management Oversight
View
Goli Zarringhalam
CAR T Case Manager
View
Michael Massello
VP of Marketing
View
Irma Loebe
CAR T Case Manager at Autolus Therapeutics
View
Diane Crombie Hogan
Clinical Site Manager
View
Mark Prygoda
Senior Director, US Market Access Strategy & Operations
View
Matthias Will
Chief Development Officer (CDO)
View

FAQ

Autolus Therapeutics operates in the Biotech industries. More details can be found on the official website: autolus.com.
The headquarters of Autolus Therapeutics are located in London, United Kingdom.
The current CEO of Autolus Therapeutics is Christian Itin
You can contact Autolus Therapeutics by phone at 44-20-3829-6230.
Autolus Therapeutics currently employs 500-1000 people.
You can contact Autolus Therapeutics by phone at 44-20-3829-6230, by email at contact@autolus.com, through social media (LinkedIn), or via the contact form on autolus.com.
Autolus Therapeutics's revenue is approximately 1.5M.
Well-known competitors of Autolus Therapeutics include INOVIO Pharmaceuticals, Inc., Kite Pharma, Immune Design and Medigene AG.
BACK TO TOP